Equities

Femasys Inc

FEMY:NAQ

Femasys Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.15
  • Today's Change-0.02 / -1.71%
  • Shares traded90.55k
  • 1 Year change+256.81%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

  • Revenue in USD (TTM)950.09k
  • Net income in USD-16.69m
  • Incorporated2004
  • Employees32.00
  • Location
    Femasys Inc3950 JOHNS CREEK COURT, SUITE 100SUWANEE 30024United StatesUSA
  • Phone+1 (770) 500-3910
  • Websitehttp://www.femasys.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inspira Technologies Oxy BHN Ltd0.00-11.29m23.23m37.00--3.44-----0.9549-0.95490.000.36660.00----0.00-88.60-114.98-108.36-159.56------------0.00------24.64------
IR-Med Inc0.00-3.47m24.05m6.00--66.22-----0.0499-0.04990.000.00510.00----0.00-197.95---273.36--------------0.3019-------3.70------
Orgenesis Inc662.00k-29.02m25.81m146.00------38.99-0.8684-0.86840.02-0.33030.027278.295.384,534.25-122.18---1,312.10---101.06---4,489.28--0.0741-5.85-----98.53-50.94-271.82---17.71--
Femasys Inc950.09k-16.69m26.01m32.00--2.31--27.38-0.8468-0.84680.04720.50600.05490.34387.6529,690.31-96.51---108.58--65.67---1,756.83--5.93-77.250.2972---11.13---25.04------
Meihua International Medical Tech Co Ltd97.10m11.63m26.22m617.002.120.16852.170.2700.48560.48564.066.110.578846.661.31157,372.606.9112.268.1315.0534.1938.1411.9415.475.21--0.04750.00-6.055.1086.22-5.56-9.16--
Retractable Technologies Inc38.25m-18.10m26.91m148.00--0.3158--0.7035-0.6046-0.60461.282.850.22021.446.42258,468.00-10.2812.45-10.7914.5119.1940.82-46.7118.096.54-2.860.016---54.025.55-249.46--17.42--
Ekso Bionics Holdings Inc18.16m-12.42m26.99m70.00--1.91--1.49-0.7909-0.79091.130.65380.59571.653.14259,428.60-40.75-43.63-57.60-57.6751.8351.93-68.41-104.241.77-23.990.3172--41.5710.03-0.7825--3.69--
bioAffinity Technologies Inc7.32m-8.74m27.12m75.00--6.73--3.71-0.9007-0.90070.74390.29890.9422236.818.6897,545.07-112.51---140.58--35.47---119.41--1.14-296.510.234--52,660.42--2.66------
Positron Corp1.24m-1.27m27.23m22.00------22.01-0.0897-0.08970.0876-0.11090.59762.296.56---61.35-224.13----32.989.85-102.67-201.870.0638-------10.060.275163.63--4.36--
Golden Valley Development Inc0.00-92.53k27.36m0.00---------11.17-11.170.00-0.02110.00-------7,710.83-------------3,073.27---3.96--------45.48------
Neuronetics Inc72.07m-32.47m28.70m203.00--1.47--0.3983-1.10-1.102.450.64330.73092.314.76355,000.00-32.93-28.02-42.47-34.7375.9175.73-45.06-51.042.37-3.920.755--9.426.2218.76--18.57--
Neuroone Medical Technologies Corp3.96m-12.10m28.81m16.00--8.65--7.27-0.4916-0.49160.15930.10820.74281.6919.31247,702.50-226.84-172.88-334.70-274.7429.60---305.37-674.971.36--0.00--62.66---18.60------
Know Labs Inc0.00-16.34m29.68m15.00---------0.2204-0.22040.00-0.05330.00----0.00-442.53-209.16---1,087.76-------1,302.62---15.986.21---100.00---1.85---3.64--
DarioHealth Corp19.15m-46.52m30.03m223.00--0.4411--1.57-1.51-1.510.58032.270.162.393.3169,373.19-42.46-73.26-47.52-87.5930.9729.54-265.33-293.541.96--0.2961---26.4122.450.5091--52.42--
Data as of Sep 20 2024. Currency figures normalised to Femasys Inc's reporting currency: US Dollar USD

Institutional shareholders

6.33%Per cent of shares held by top holders
HolderShares% Held
CM Management LLCas of 30 Jun 2024425.00k1.91%
Clear Creek Financial Management LLCas of 30 Jun 2024317.47k1.43%
The Vanguard Group, Inc.as of 30 Jun 2024192.67k0.87%
Geode Capital Management LLCas of 30 Jun 2024189.01k0.85%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202470.98k0.32%
SSgA Funds Management, Inc.as of 30 Jun 202456.37k0.25%
City National Rochdale LLCas of 30 Jun 202452.94k0.24%
BlackRock Fund Advisorsas of 30 Jun 202435.68k0.16%
HB Wealth Management LLC (GA)as of 30 Jun 202435.47k0.16%
Tri Locum Partners LPas of 30 Jun 202430.61k0.14%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.